CDC Multiplex Assay Receives Authorization from FDA

COLA is engaged with the CDC’s Laboratory Outreach Communication System (LOCS) in the Division of Laboratory Systems (DLS) to transmit their public health messages to our COLA laboratories and affiliates. Below is a link to the most recent message about FDA authorization of CDC’s multiplex assay.

Lab Advisory: CDC Multiplex Assay Receives Authorization from FDA

On July 2, 2020, FDA granted an Emergency Use Authorizationexternal icon (EUA) for the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay, a real-time RT-PCR test that detects and differentiates RNA from SARS-CoV-2, influenza A virus, and influenza B virus in upper or lower respiratory specimens. For general information on the Influenza SARS-CoV-2 Multiplex Assay, refer to the CDC Frequently Asked Questions about COVID-19 for Laboratories.

Read more here.